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Introduction
Inhalation of (antimicrobial) drugs is a cornerstone in the treatment of patients with cystic fibrosis (Döring et al., 2000) . The currently available antimicrobial drugs for inhalation, tobramycin and colistimethate sodium, are commercially available as solution for nebulisation only. Although both drugs are widely used, the lack of convenience and efficiency regarding pulmonary administration of tobramycin and colistimethate sodium is a drawback for cystic fibrosis patients (Le Brun et al., 2000a) . Dry powder inhalation of these drugs may therefore be an attractive alternative to nebulisation.
Nebulisation of liquids is a complex procedure that is affected by many different factors, which may furthermore show various interactions and mutual dependencies. Major factors influencing the outcome of nebulisation treatment with jet nebulisers are the breathing pattern and adherence to therapy (Laube et al., 2000; Kettler et al., 2002; Brand et al., 2005) , the physico-chemical properties of the drug solution, the design of the nebuliser in relation to the jet flow pressure, the cleaning of the apparatus (Hutchinson et al., 1996; Standaert et al., 1998) , the nebulisation time and the complex 'interactions' that may exist between (some of ) these parameters (Hurley 1994; Ferron 1996; McCallion et al., 1996; Coates et al., 1997; Le Brun et al., 1999a; Katz et al., 2001; Standaert 2001; De Boer et al., 2003) .
In contrast, dry powder inhalation is a relatively simple mode of drug administration. Major advantages of a dry powder inhaler over nebuliser-compressor combinations are the timeefficient way of drug administration and ease of portability. An efficient inhaler device, a dry powder formulation with an optimal particle size in relation to the target area and an adequate inspiratory flow rate are the basic requirements for an efficacious dry powder inhalation.
Information on dry powder inhalers has recently been reviewed (Frijlink and De Boer 2004; Rau 2005; Telko 2005 ). De Boer et al. (2006) described the properties of a new dry powder inhaler concept for high drug doses in development (Twincer ® ), that is capable to deliver relatively large amounts of dry powder into the lungs.
In cystic fibrosis, the main target area for pulmonary administered drugs is the peripheral part of the airways. Therefore, dry powder particle size should be within the 1-5 μm range (=fine particle fraction) (Bates 1966; Zanen 1996) . The inspiratory flow rate should be relatively low for dry powder particles in order to reach the small airways and to avoid impaction (due to high flow rates) in the oropharynx as much as possible. Because the inspiratory muscles in CF are normal and maximal inspiratory flow in most CF patients is comparable to that in healthy volunteers, CF patients are capable of generating high flow rates through a DPI (Sarinas et al., 1998) . For these reasons, the air flow resistance of the Twincer ® used for this study was kept relatively high (0.040 kPa 0.5 min l −1 ) in order to reduce the flow rate through the DPI.
Several clinical studies have been published on dry powder inhalation in cystic fibrosis.
Tobramycin was tested by Newhouse et al. (2003) in healthy volunteers; dry powder inhalation of gentamicin has been described by Crowther Labiris et al. (1999) (3 CF patients and 7 patients with bronchiectasis) and Goldman et al. (1990) (forty patients undergoing routine bronchoscopy); colistin sulfate has been tested by Le Brun et al. (2002) (6 healthy volunteers and 5 CF patients) and colistimethate sodium in 8 healthy volunteers by Westerman et al. (2007) .
The Twincer ® inhaler device, used in the volunteer study by Westerman et al. (2007) and in the current study, is a multi air classifier based inhaler under development, having two parallel classifiers in the same plane. It has the approximate size of a credit card (Fig. 1) . This disposable inhaler is designed for single use and for delivery of large powder doses. The powder dose is kept in a blister, preventing possible adverse effects of moisture on the dry powder and subsequently on inhaler efficiency. Several inhaler experiments have been performed in vitro. The powder formulation of colistimethate sodium is a physical mixture of the micronized drug with sweeper crystals (16.7%). The function of these crystals, as described more in detail previously (De Boer et al., 2006) , is to sweep micronised drug particles from the walls of both classifiers during inhalation. The crystalline particles are retained by the two classifiers because of their large diameters (150-200 μm): only particles <10 μm are released. The micronized colistimethate sodium in this formulation has a (volume) median diameter, measured with laser diffraction apparatus, of 1.6 μm (X 10 =0.7 μm, X 90 =3.1 μm). The median diameter of the colistimethate sodium in the aerosol from the Twincer ® inhaler is comparable at flow rates of 30 l/min and 60 l/min. The fine particle fraction (<5 μm) was 43.8% at 34 l/min (1 kPa), 48.0% at 48 l/min (2 kPa) and 50.6% at 67 l/min (4 kPa) after a dose of 2×12.5 mg colistimethate sodium, indicating that emission of the dose from the inhalation device is to a great extent independent of the inspiratory flow. The in vitro tests have been described by De Boer (De Boer et al., 2006) .
The objectives of this pilot study were to assess the feasibility, including tolerability and potential clinical use of the colistimethate sodium dry powder Twincer ® inhaler by a single dose 
Design

Feasibility assessment
Tolerability was assessed by monitoring adverse effects after inhalation, by measuring pulmonary function at standardised time-points and to compare these results to the data obtained after a single nebulised dose of colistimethate sodium. Pulmonary deposition of the dry powder was assessed by using serum concentrations of colistin components as a surrogate parameter for peripheral pulmonary deposition and, again, compared to the serum concentrations measured after an single nebulised dose of colistin in each individual patient.
Study population
Ten patients on maintenance treatment with colistimethate sodium, visiting the outpatient clinic, were asked to participate in an open, randomised, crossover study. Inclusion and exclusion criteria are listed in Table 1 . As this study was intended as a pilot study, applying an inhaler under development, no special requirements were made on the inclusion (e.g. disease state, FEV 1 ) of the participants. Each participant was its own control. Subjects' characteristics are shown in Table 2 . Patients were asked to stop their regular nebulisation of colistimethate sodium 3 days prior to each study visit. The study was approved of by the ethical review board of the hospital and was performed according to the Helsinki declaration.
Written informed consent to participate in the study was obtained from all patients before commencing any protocol-specified procedure. On two separate days, the patients inhaled a single dose of colistimethate sodium in a dry powder formulation or nebulised the colistimethate sodium solution. The order of treatment was determined by randomisation. A minimum of 3 days and a maximum of 10 days were allowed between visits 1 and 2.
Study drug Dry powder inhalation (DPI)
One dose of the dry powder consisted of two inhalations of 12.5 mg colistimethate sodium each. The powder mixture was composed of colistimethate sodium 83.3% and lactose sweeper crystals 16.7%, resulting in a total dose of 25 mg colistimethate sodium and 5mg lactose (fraction 150-200 μm from Pharmatose 100M, DMV International, Veghel, The Netherlands).
Colistimethate sodium (Ph. Eur quality, sterile, Alpharma, Copenhagen, Denmark; 13,200 units/ mg) was micronised to obtain a particle size in the 1-5 μm range, using a jet mill (50 AS, Alpine, Augsburg, Germany). Particle size reduction and filling of the inhaler with the colistin-lactose mixture was performed in the hospital pharmacy according to good manufacturing practice (GMP) guidelines. Prior to inhalation the patients were trained for the inhalation manoeuvre using an empty inhaler connected to an electronic inspiratory flow measurement device (University of Groningen, Groningen, The Netherlands). Maximal inspiratory flow rate (l/min) and inhalation time (s) were measured when the inhalation manoeuvre could be performed consistently. Inhalation of the colistin dry powder dose was done immediately after instruction. Participants were instructed to perform a deep and powerful inhalation during 2-3 s and to hold their breath during a few seconds. After inhalation, the patients were observed and asked for adverse effects. An interval of 2 min between the two dry powder inhalations was offered in case of adverse effects (e.g. cough). However, none of the patients used this facility.
Nebulisation
One dose of drug solution for nebulisation consisted of 2 million units colistimethate sodium.
The exact dose of 158 mg was calculated using the activity of the colistimethate sodium batch (Ph. Eur quality, sterile, Alpharma, Copenhagen, Denmark; approx. 13,200 units/mg) and dissolved in 6 ml of sterile NaCl 0,9% solution by the hospital pharmacy. To prevent spill of colistin solution due to foaming during nebulisation, the dose was transferred to the nebuliser cup in two portions of 3 ml. The drug was nebulised using a Ventstream ® jet nebuliser and a Portaneb ® compressor (Medic Aid, Romedic, Meerssen, The Netherlands). Patients were instructed to continue nebulisation until the inhaler started sputtering.
Actual dose
The dry powder inhaler contained a nominal dose of 25 mg (drug dose label claim), the nebuliser cup a nominal dose of 158 mg (drug dose label claim) of colistimethate sodium. After inhalation or nebulisation, a fraction of the dose remains in the inhalation device. For determination of the fraction of the drug remaining in the inhalation device a modification of the Lowry protein assay was used (Lowry et al., 1951) . The actual dose is the amount of drug that has been emitted from the inhalation device and can be calculated by subtracting the amount of drug retained in the device from the nominal dose.
Pulmonary function
Pulmonary function tests were performed before, 5 and 30 min after inhalation or nebulisation.
Forced expiratory volume in one second (FEV 1 ) and forced vital capacity (FVC) were measured using a calibrated Masterlab pneumotachograph (Jaeger, Würzburg, Germany (Quanjer et al., 1993) . Change (percentage) in lung function is relative to baseline, and not a percentage fall of predicted. A reduction in FEV 1 of 10% or more was considered to be clinically relevant. Patients were observed and asked for adverse effects during this period.
Blood sampling and analysis
Serum concentrations have been used in this study to reflect peripheral pulmonary deposition in an indirect way. Venous blood samples were collected from patients prior to the colistin dose and at 15, 45 min, 1.5; 2.5; 3.5 and 5.5 h after inhalation or nebulisation, on both study days.
Serum samples were stored at −70 °C prior to analysis. Sample analysis was performed using a modified High Pressure Liquid Chromatographic (HPLC) assay (Le Brun et al., 2000b) after forced hydrolysation (2 h at 60 °C) with a lower limit of quantification of 11 μg/l. Serum concentrations were determined by relating the total peak area of the E1 and E2 components of colistin to a calibration curve. No interference of the assay by co-medication of the patients was observed.
Pharmacokinetic analysis
The pharmacokinetic profile (AUC, C max , t max ) of colistin was used as an indirect method to compare pulmonary deposition of the two ways of administration of colistin in patients.
Serum concentrations and patient characteristics were imported into MW\Pharm software (version 3.58, MediWare, Groningen, The Netherlands; Proost and Meijer 1992) . This computer program offers the possibility to calculate pharmacokinetic parameters (see Table 4) 
Questionnaire
The patients were asked questions concerning their daily use of nebulised colistimethate sodium in relation to the new dry powder inhalation method.
Statistical analysis
The Kolmogorov-Smirnov test was used to test the data for normal distribution. The Student's paired t-test for changes within groups was applied to compare both inhalation methods. Data are expressed by means and standard deviation or confidence intervals. A p-value of 0.05 was considered to be statistically significant.
Results
Pulmonary function test
The colistimethate sodium dry powder was well tolerated by the patients. No clinically relevant reduction in FEV 1 was seen after inhalation of the dry powder at t=5 and t=30 min. After liquid nebulisation, patients 2 and 7 had a transient reduction in FEV 1 at t=5 min of 11.4% and 12.8% respectively, which had improved at t=30 min. Patients 4 and 7 showed a reduction in FVC at t=5 min after dry powder inhalation of 13.9% and 16.3% and patients 2 and 7 had a reduction of 15.1% and 12.7% after liquid nebulisation respectively. The FVC improved for all patients after 30 min except for patient 4 after DPI. The FVC of this patient remained at approx. 95% of predicted at t=1 and t=4 h (data not shown). See Table 3 .
Mean peak inspiratory flow rate through the empty inhaler device was 67.9 L/min (range 56.5-83.8); mean inhalation time was 2.7 s (range 1.9-4.3).
Colistin pharmacokinetics
An overview of the pharmacokinetic results is displayed in Table 4 
Questionnaire
All patients were accustomed to nebulisation of colistimethate sodium twice daily. Four patients indicated that they experienced tolerable adverse effects during or shortly after nebulisation of colistimethate sodium at home (Fig. 3) . Daily life activities were not influenced by these effects.
Three patients used a bronchodilator in combination with colistimethate sodium nebulisation.
Nine participants rated their experience with the dry powder inhaler as 'positive' or 'excellent' .
One participant did not appreciate the mouthpiece of the inhaler and scored 'good' . Four patients indicated the adverse effects during or after DPI as minor. Most patients experienced transient mild cough immediately after inhalation which was classified as 'seen with the use of other DPIs' and was rated as 'minor' or not rated at all ('none').
Discussion
The objectives of this pilot study were to assess the feasibility, including tolerability and potential clinical use of the colistimethate sodium dry powder Twincer ® inhaler by a single dose in cystic fibrosis patients and to compare the collected data by this inhalation method in each individual patient to data obtained after nebulisation of colistimethate sodium. The study was performed in 10 CF patients and the results can therefore not be extrapolated to the CF population in general. The inhaler was well tolerated by the patients: no clinically relevant reduction in FEV 1 was observed and all patients were enthusiastic about using the inhaler. Two patients showed a decrease in FVC following both dry powder inhalation and liquid nebulisation. Patient 4, known for bronchial hyperreactivity, reacted on both inhalation methods. However, this patient noticed airway narrowing after nebulisation only and not after dry powder inhalation. As the FVC remained at approx. 95% of predicted at t=1 and t=4 h after DPI, it may possibly be that the baseline FVC value of this patient on that day (102% of predicted, compared to baseline 93% of predicted on the second trial day; 7 days apart) should be considered as an outlier.
The AUC 0-4 , C max and t max after DPI (25 mg colistimethate sodium) were significantly lower than after nebulisation (158 mg colistimethate sodium), therefore no equivalence between both colistin administrations could be demonstrated. To our knowledge, no data on colistin nebulisers between 1% and 32% has been reported, depending on nebulising principle (f.e. jet or ultrasonic) and the patient's breathing pattern (Newman 1983; O'Callaghan 1997) . In a previous study on aerosolized tobramycin a deposition efficiency of approximately 10% was found (Touw et al., 1997; Le Brun et al., 1999b) . Using an identical nebuliser-compressor combination, the estimated dose of colistimethate sodium reaching the target area will therefore be approximately 16 mg. Based on a dosing efficiency of colistimethate sodium in the Twincer ® inhaler of approximately 60% (De Boer et al., 2006) , the amount of colistimethate sodium dry powder to be inhaled would be approximately 25 mg colistimethate sodium (excluding excipient) to obtain an equivalent dose. This dose corresponds with 2 inhalations. Based on this calculation and the narrow size distribution for the fine particles in the aerosol, at least an equivalent C max or AUC 0-4 between both methods of administration was expected. However, we were not able to prove equivalence of a colistimethate sodium dry powder dose of 25 mg administered by the Twincer ® inhaler to 158 mg colistimethate sodium administered by nebulisation.
The pharmacokinetic parameters C max , t max and AUC provide information concerning the bioavailability of a drug. In a study in which dry powder inhalation is compared to nebulisation, AUC is probably the best parameter for comparison, as a difference in administration time exists Question Score
Concerning colistin use at home 1a. How many times a day do you nebulise colistin? 1b. Do you experience adverse effects during or after nebulisation? 2. When do these adverse effects occur?
3. Do these adverse effects influence your daily life?
4. Do you use other (inhalation)drugs to decrease chest tightness after nebulisation?
Concerning colistin dry powder inhaler (study) 1. What is your experience with the colistin dry powder inhaler?
(1 = very bad, 6 = excellent) 2. Did you experience adverse effects during or after nebulisation? 3. When did these effects occur? between dry powder inhalation (approx. 1 min) and nebulisation (approx. 15-20 min) that will be of influence on the C max and t max . Theoretically, many factors will have contributed to this result. Most prominent is the relation between particle size distribution, inspiratory flow rate and pulmonary deposition. Although a large fine particle fraction is supposed to correspond with a high peripheral deposition and subsequently a relatively large amount of absorption into the blood stream, this process can be suboptimal if the inspiratory flow rate is too high (causing impaction in the oropharynx) or the particle size is too small (leading to exhalation of the drug) or too large (when the drug does not reach the small airways). In vitro deposition experiments do not reflect in vivo administration, and we cannot rule out the possibility that a relatively high fraction of the dose has been deposited in the oropharynx due to the high inspiratory flow (range 56-84 l/min) generated by the patients. Furthermore, we hypothesize that part of the dose could have been exhaled from the periphery of the lung due to very small particles in the aerosol despite the fact that patients were instructed to hold their breath during a few seconds after inhalation. The absolute lower deposition after DPI compared to nebulisation may be an explanation for the difference of observed airway narrowing seen in some patients after nebulisation but not after DPI. A lower deposition stands for less exposure to colistin particles and therefore a lower risk of airway narrowing.
Dry powder inhalation of the sulfate salt of colistin has been described by Le Brun et al., (2002) . In this pilot study, colistin sulfate was administered using an inhaler based on the cyclone principle by de Boer et al., (2002) . Although the dry powder inhalation was appreciated by the patients, some experienced serious cough as adverse effect. This appeared to be a result of the chemical structure of the colistin sulfate salt and it was concluded that colistimethate sodium, which is currently used by many CF patients by nebulisation, is the colistin salt of choice for further development of a dry powder inhaler (Westerman et al., 2004) . Serum concentration results from the study by Le Brun (Le Brun et al., 2002) and the current study should be compared with caution, as data obtained in the Le Brun study are retrieved from a different dry powder inhaler and from both colistin sulfate (DPI) and colistimethate sodium (nebulisation) administration, while only colistimethate sodium was used in the current study.
Interindividual variation in serum concentrations was remarkable and corresponds with other data on dry powder inhalation (Westerman et al., 2007 , Cochrane et al., 2000 Aswania et al., 2004) . The population in this study consisted of CF patients in different conditions regarding FEV 1 (range 32-104%) and this may have contributed to the observed range of serum concentrations. Little is known about the absorption mechanism of colistin from the (peripheral) airways into the bloodstream. Several mechanisms have been described by which drug molecules can enter the bloodstream from the alveoli (Patton 1996; Tronde et al., 2003) but no data are available on absorption of colistin, nor is there information on comparing absorption of fluid particles to dry particles. Next to physical and chemical properties of the drug in question, lung morphology (for example extent of fibrosis and amount of sputum) probably plays an important role. No contribution to serum concentrations is to be expected as a result of gastrointestinal absorption following ingested colistimethate sodium during inhalation (Westerman et al., 2007) .
A future study will focus on using the Twincer ® inhaler with a dry powder formulation with a slightly larger mass median diameter, an intermediate inspiratory flow rate (40-50 l/min) and a breath hold of approximately 10 s. The inspiratory flow rate is inversely proportional to the internal resistance of an inhaler (Sarinas et al., 1998; Kettler et al., 2002) . Applying an intermediate inspiratory flow rate when using an identical Twincer ® inhaler will result in adjustment of the aerodynamic deposition behaviour of the dry particles and an optimal deposition in the target area of the lung. Secondly, it is expected that the larger particle size will reduce the fraction of the dry powder that is exhaled, resulting in a higher (peripheral) deposition, which will be consolidated by breath holding.
In conclusion, this first clinical study on dry powder inhalation of colistimethate sodium using the Twincer ® inhaler has shown that the drug is well tolerated and appreciated by cystic fibrosis patients. Optimisation with respect to particle size and inspiratory flow rate is necessary to attain comparable pulmonary deposition after liquid nebulisation. This will be incorporated in a future study.
